title: Severe pulmonary complications after bortezomib treatment for multiple myeloma: an unrecognized pulmonary vasculitis?
authors.forename: Vincenzo
authors.initials: V
authors.lastname: Pitini
authors.forename: Carmela
authors.initials: C
authors.lastname: Arrigo
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Altavilla
authors.forename: Claudia
authors.initials: C
authors.lastname: Naro
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001897:Boronic Acids / Q000009:adverse effects* / Q000627:therapeutic use; D000069286:Bortezomib; D006801:Humans; D008171:Lung Diseases / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D010996:Pleural Effusion / Q000139:chemically induced / Q000188:drug therapy; D011719:Pyrazines / Q000009:adverse effects* / Q000627:therapeutic use; D012131:Respiratory Insufficiency / Q000139:chemically induced / Q000188:drug therapy; D014657:Vasculitis / Q000139:chemically induced* / Q000188:drug therapy
chemical_list: D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D000069286:Bortezomib